# Single‐Cell RNAseq Identifies Heterogeneity in Myoblasts From Older Adults With Differences Related to Muscle Mass and Function

**Authors:** Mark A. Burton, Emma S. Garratt, Hanan Y. Sharkh, Matthew O. Hewitt, Elie Antoun, Leo D. Westbury, Elaine M. Dennison, Nicholas C. Harvey, Cyrus Cooper, Harnish P. Patel, Keith M. Godfrey, Karen A. Lillycrop

PMC · DOI: 10.1002/jcsm.70213 · Journal of Cachexia, Sarcopenia and Muscle · 2026-02-17

## TL;DR

This study uses single-cell RNA sequencing to show that muscle stem cells in older adults vary in gene activity, with differences linked to muscle mass and strength.

## Contribution

The study reveals transcriptional heterogeneity in myoblasts from older adults and links it to muscle health indicators like mass and grip strength.

## Key findings

- Thirteen distinct myoblast clusters were identified, with most cells in clusters 0–6.
- Individuals with higher muscle mass and strength had more cells in clusters associated with muscle development and RNA processing.
- Cells from individuals with low muscle mass and strength were more likely to transition toward fibrogenic or stressed states.

## Abstract

Ageing is associated with the loss of muscle mass and function, with consequences for metabolic health, frailty and independence in later life. The aim of this study was to investigate the transcriptional heterogeneity of human proliferating muscle satellite/stem cells (myoblasts) from older adults and how this heterogeneity may vary between healthy individuals and those with low muscle mass and function.

Single‐cell transcriptomic analysis was carried out on proliferating myoblasts isolated from vastus lateralis biopsies from 132 participants (34 male, 98 female) aged 72–83 years from the Hertfordshire Sarcopenia Study extension. Uniform Manifold Approximation and Projection (UMAP) clustering was applied to identify clusters of myoblasts with distinct transcriptional profiles, Gene Ontology analysis was used to identify pathways enriched among the clusters, and pseudotime trajectory analysis was used to identify inferred cell lineages. Differential gene expression within cell clusters, together with the proportions of cells within each cluster and lineage, were assessed with respect to participant appendicular lean‐mass index (ALMi), grip strength, and gait speed.

Thirteen distinct cell clusters based on the transcriptional heterogeneity of the myoblasts were identified. Clusters 0–6 contained the majority (94.6%) of cells. Marker genes were enriched for cytoplasmic translation (Cluster 0, false discovery rate [FDR] = 7.21 × 10−63), muscle development (Cluster 1, FDR = 2.25 × 10−13), cell proliferation (Clusters 2, 4 and 6, all FDR ≤ 0.05), extracellular matrix organisation (Cluster 3, FDR = 1.92 × 10−45) and RNA processing (Cluster 5, FDR = 1.89 × 10−08). Individuals with the highest grip strength and ALMi had a greater proportion of Cluster 1 and Cluster 5 cells. Gene expression analysis (FDR ≤ 0.05) within the clusters identified 22 differentially expressed transcripts with respect to ALMi in Cluster 2 and 13 with respect to grip strength in Cluster 1. Inferred lineage analysis identified cells transitioning along five trajectories (L1–L5), including cells in L1, L3 and L4 progressing towards a stressed pre‐senescent/senescent (L1) or fibrogenic (L3 and L4) state, with cells in these lineages being more likely to originate from individuals with low ALMi (χ2
p = 1.11 × 10−146) and grip strength (χ2
p = 1.31 × 10−269).

Our findings demonstrate considerable transcriptional heterogeneity in skeletal muscle myoblasts from older adults. This heterogeneity includes myoblasts from individuals with low muscle mass and strength progressing towards a fibrogenic or stressed state.

## Linked entities

- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** COX5B (cytochrome c oxidase subunit 5B) [NCBI Gene 1329] {aka COXVB}, COL4A1 (collagen type IV alpha 1 chain) [NCBI Gene 1282] {aka BSVD, BSVD1, COL4A1s, PADMAL, RATOR}, HMGN2 (high mobility group nucleosomal binding domain 2) [NCBI Gene 3151] {aka HMG17}, SALL2 (spalt like transcription factor 2) [NCBI Gene 6297] {aka COLB, HSAL2, Sal-2, ZNF795, p150(Sal2)}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, MYBL2 (MYB proto-oncogene like 2) [NCBI Gene 4605] {aka B-MYB, BMYB}, PPARGC1A (PPARG coactivator 1 alpha) [NCBI Gene 10891] {aka LEM6, PGC-1(alpha), PGC-1alpha, PGC-1v, PGC1, PGC1A}, MMP2 (matrix metallopeptidase 2) [NCBI Gene 4313] {aka CLG4, CLG4A, MMP-2, MMP-II, MONA, TBE-1}, RPS7 (ribosomal protein S7) [NCBI Gene 6201] {aka DBA8, S7, eS7}, CSNK1G1 (casein kinase 1 gamma 1) [NCBI Gene 53944] {aka CK1gamma1}, PABPC1 (poly(A) binding protein cytoplasmic 1) [NCBI Gene 26986] {aka PAB1, PABP, PABP1, PABPC2, PABPL1}, SNRNP35 (small nuclear ribonucleoprotein U11/U12 subunit 35) [NCBI Gene 11066] {aka HM-1, HM1, U1SNRNPBP}, Fn1 (fibronectin 1) [NCBI Gene 14268] {aka E330027I09, Fn, Fn-1}, CENPK (centromere protein K) [NCBI Gene 64105] {aka AF5alpha, CENP-K, FKSG14, P33, Solt}, TOM1 (target of myb1 membrane trafficking protein) [NCBI Gene 10043] {aka IMD85}, RPL31 (ribosomal protein L31) [NCBI Gene 6160] {aka L31, eL31}, POSTN (periostin) [NCBI Gene 10631] {aka OSF-2, OSF2, PDLPOSTN, PN}, NDUFB3 (NADH:ubiquinone oxidoreductase subunit B3) [NCBI Gene 4709] {aka B12, CI-B12, MC1DN25}, CDKN1A (cyclin dependent kinase inhibitor 1A) [NCBI Gene 1026] {aka CAP20, CDKN1, CIP1, MDA-6, P21, SDI1}, REXO2 (RNA exonuclease 2) [NCBI Gene 25996] {aka CGI-114, REX2, RFN, SFN}, PPBP (pro-platelet basic protein) [NCBI Gene 5473] {aka B-TG1, Beta-TG, CTAP-III, CTAP3, CTAPIII, CXCL7}, NDUFB6 (NADH:ubiquinone oxidoreductase subunit B6) [NCBI Gene 4712] {aka B17, CI}, RPS18 (ribosomal protein S18) [NCBI Gene 6222] {aka D6S218E, HKE3, KE-3, KE3, S18, uS13}, SPARC (secreted protein acidic and cysteine rich) [NCBI Gene 6678] {aka BM-40, OI17, ON, ONT}, SAA1 (serum amyloid A1) [NCBI Gene 6288] {aka PIG4, SAA, TP53I4}, IGFBP7 (insulin like growth factor binding protein 7) [NCBI Gene 3490] {aka AGM, FSTL2, IBP-7, IGFBP-7, IGFBP-7v, IGFBPRP1}, PARP1 (poly(ADP-ribose) polymerase 1) [NCBI Gene 142] {aka ADPRT, ADPRT 1, ADPRT1, ARTD1, PARP, PARP-1}, H19 (H19 imprinted maternally expressed transcript) [NCBI Gene 283120] {aka ASM, ASM1, BWS, D11S813E, GMRSP, LINC00008}, WNT10A (Wnt family member 10A) [NCBI Gene 80326] {aka ECTD16, OODD, SSPS, STHAG4}, TCF19 (transcription factor 19) [NCBI Gene 6941] {aka SC1, TCF-19}, MKI67 (marker of proliferation Ki-67) [NCBI Gene 4288] {aka KIA, MIB-, MIB-1, PPP1R105}, KRT7 (keratin 7) [NCBI Gene 3855] {aka CK7, K2C7, K7, SCL}, NQO1 (NAD(P)H quinone dehydrogenase 1) [NCBI Gene 1728] {aka DHQU, DIA4, DTD, NMOR1, NMORI, QR1}, RPL10 (ribosomal protein L10) [NCBI Gene 6134] {aka AUTSX5, DXS648, DXS648E, L10, MRXS35, NOV}, BAZ2B (bromodomain adjacent to zinc finger domain 2B) [NCBI Gene 29994] {aka WALp4}, FTH1 (ferritin heavy chain 1) [NCBI Gene 2495] {aka FHC, FTH, FTHL6, HFE5, NBIA9, PIG15}, TNNT2 (troponin T2, cardiac type) [NCBI Gene 7139] {aka CMD1D, CMH2, CMPD2, LVNC6, RCM3, TnTC}, RPL30 (ribosomal protein L30) [NCBI Gene 6156] {aka L30, eL30}, CTSZ (cathepsin Z) [NCBI Gene 1522] {aka CTSX}, MGST1 (microsomal glutathione S-transferase 1) [NCBI Gene 4257] {aka GST12, MGST, MGST-I, PMAN}, MYF5 (myogenic factor 5) [NCBI Gene 4617] {aka EORVA, bHLHc2}, PHKB (phosphorylase kinase regulatory subunit beta) [NCBI Gene 5257], NCAM1 (neural cell adhesion molecule 1) [NCBI Gene 4684] {aka CD56, MSK39, NCAM}, CDK2 (cyclin dependent kinase 2) [NCBI Gene 1017] {aka CDKN2, p33(CDK2)}, PI16 (peptidase inhibitor 16) [NCBI Gene 221476] {aka CD364, CRISP9, MSMBBP, PSPBP}, RPS14 (ribosomal protein S14) [NCBI Gene 6208] {aka EMTB, S14, uS11}, ACTN1 (actinin alpha 1) [NCBI Gene 87] {aka BDPLT15}, COX6A1 (cytochrome c oxidase subunit 6A1) [NCBI Gene 1337] {aka CMTRID, COX6A, COX6AL}, RPS23 (ribosomal protein S23) [NCBI Gene 6228] {aka BTDD, MABAS, MCINS, PAMAS, S23, uS12}, NDC1 (NDC1 transmembrane nucleoporin) [NCBI Gene 55706] {aka NEDAPA, NET3, TMEM48}, CD248 (CD248 molecule) [NCBI Gene 57124] {aka CD164L1, TEM1}, COX8A (cytochrome c oxidase subunit 8A) [NCBI Gene 1351] {aka COX, COX8, COX8-2, COX8L, MC4DN15, VIII}, Wnt5a (wingless-type MMTV integration site family, member 5A) [NCBI Gene 22418] {aka 8030457G12Rik, Wnt-5a}, GABARAPL2 (GABA type A receptor associated protein like 2) [NCBI Gene 11345] {aka ATG8, ATG8C, GATE-16, GATE16, GEF-2, GEF2}, DDX5 (DEAD-box helicase 5) [NCBI Gene 1655] {aka G17P1, HLR1, HUMP68, p68}, BRCA2 (BRCA2 DNA repair associated) [NCBI Gene 675] {aka BRCC2, BROVCA2, FACD, FAD, FAD1, FANCD}, WNT5A (Wnt family member 5A) [NCBI Gene 7474] {aka hWNT5A}, HMGB2 (high mobility group box 2) [NCBI Gene 3148] {aka HMG2}, RGPD2 (RANBP2 like and GRIP domain containing 2) [NCBI Gene 729857] {aka NUP358, RANBP2L2, RGP2, ranBP2-like 2}, AKR1C4 (aldo-keto reductase family 1 member C4) [NCBI Gene 1109] {aka 3-alpha-HSD, C11, CDR, CHDR, DD-4, DD4}
- **Diseases:** Cachexia (MESH:D002100), myofibrillar myopathy (MESH:C580316), muscle dysregulation (MESH:D021081), frailty (MESH:D000073496), Muscle Mass (MESH:C536030), Sarcopenia (MESH:D055948), muscle atrophy (MESH:D009133), inflammatory (MESH:D007249), muscle (MESH:D019042), tumour (MESH:D009369), diabetes (MESH:D003920), breast cancer type 1 and type II (MESH:D001943), ALMi (MESH:D013851), ischaemic heart disease (MESH:D006331), Reduced muscle mass and strength (MESH:D009135), neuromuscular conditions (MESH:D009468), Arthritis (MESH:D001168), CKD (MESH:D012080), Osteoporosis (MESH:D010024), C1 (MESH:D003027)
- **Chemicals:** ROS (MESH:D017382)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** C2 — Homo sapiens (Human), Neuroblastoma, Cancer cell line (CVCL_0529), C10 — Homo sapiens (Human), Induced pluripotent stem cell (CVCL_C7T6), C5 — Mus musculus (Mouse), Transformed cell line (CVCL_5U93), S2 — Drosophila melanogaster (Fruit fly), Spontaneously immortalized cell line (CVCL_Z232), C1 — Mus musculus (Mouse), Hybridoma (CVCL_C7RB), C12 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0188), C03 — Homo sapiens (Human), Melanoma, Cancer cell line (CVCL_C6NK), C0 — Homo sapiens (Human), Familial hypertrophic cardiomyopathy type 26, Induced pluripotent stem cell (CVCL_A6XE), C3 — Mus musculus (Mouse), Hybridoma (CVCL_C6V6), C02 — Homo sapiens (Human), Melanoma, Cancer cell line (CVCL_VU41), L5 — Rattus norvegicus (Rat), Rat hepatocellular carcinoma, Cancer cell line (CVCL_F951)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12913704/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12913704/full.md

## References

40 references — full list in the complete paper: https://tomesphere.com/paper/PMC12913704/full.md

---
Source: https://tomesphere.com/paper/PMC12913704